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Background: Systemic sclerosis (SSc) is characterized by vascular alteration and fibrosis, the former probably leading to
fibrosis via the ability of both endothelial cells and pericytes to differentiate toward myofibroblast. It is well known that
vascular endothelial growth factor A (VEGF-A, hereafter referred to as VEGF) may induce a profibrotic phenotype on
perivascular cells. Caveolin-1 (Cav-1) is involved in the regulation of VEGF signaling, playing a role in the transport of
internalized VEGF receptor 2 (VEGFR2) toward degradation, thus decreasing VEGF signaling. In this work, we assessed the
levels of Cav-1 in SSc bone marrow mesenchymal stem cells (SSc-MSCs), a pericyte surrogate, and correlate these results
with VEGF signaling, focusing onpotential pathogenic pathways leading to fibrosis.
Results: We explored the VEGF signaling assessing: (1) Cav-1 expression; (2) its co-localization with VEGFR2; (3) the activity
of VEGFR2, by IF, immunoprecipitation, and western blot. In SSc-MSCs, Cav-1 levels were lower when compared to healthy
controls (HC)-MSCs. Furthermore, the Cav-1/VEGFR2 co-localization and the ubiquitination of VEGFR2 were impaired in
SSc-MSCs, suggesting a decreased degradation of the receptor and, as a consequence, the tyrosine phosphorylation of
VEGFR2 and the PI3-kinase-Akt pathways were significantly increased when compared to HC. Furthermore, an increased
connective tissue growth factor (CTGF) expression was observed in SSc-MSCs. Taken together, these data suggested the
upregulation of VEGF signaling in SSc-MSCs. Furthermore, after silencing Cav-1 expression in HC-MSCs, an increased CTGF
expression in HC-MSCs was observed, mirroring the results obtained in SSc-MSCs, and confirming the potential role that
the lack of Cav-1 may play in the persistent VEGF signaling .
Conclusions: During SSc, the lower levels of Cav-1 may contribute to the pathogenesis of fibrosis via an upregulation of
the VEGF signaling in perivascular cells which are shifted to a profibrotic phenotype.
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Systemic sclerosis (SSc) is a chronic autoimmune con-
nective tissue disease affecting the skin and a variety of
internal organs. The hallmark of the early stages of SSc
is endothelial involvement, with a perivascular inflam-
matory infiltrates and a decreased capillary density [1],
whereas later stages are characterized by an excessive
accumulation of extracellular matrix (ECM), resulting
in fibrosis [2,3]. The vascular alterations might be* Correspondence: paola.cipriani@cc.univaq.it
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endothelial cells and pericytes, after injuries, might
trans-differentiate toward myofibroblast, a cell produ-
cing increased amounts of collagen types I, III, VI, and
VII, fibronectin, and glycosaminoglycans [4].
Originally, myofibroblasts were thought to derive from
resident fibroblasts which, after the interaction with ef-
fector molecules in injured tissues, might be activated,
thus leading to reparative fibrotic response. More re-
cently, it has been suggested that these cells may be
generated by both epithelial-mesenchymal and endothelial-
mesenchymal transformation [5-7]. In the last years, the
use of lineage tracing, helped us to better define thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cytes and resident fibroblasts are the major, if not the only,
source of myofibroblasts in at least one animal model of
kidney fibrotic diseases [8-10]. On these bases, it might be
important to assess if the molecular mechanisms involved
in the differentiation of pericytes toward myofibroblasts
may play a role in the pathological process leading to fibro-
sis during SSc.
Recent works showed that perivascular cells share sur-
face markers and differentiative ability with bone mar-
row mesenchymal stem cells (MSCs), and MSCs express
pericyte markers and cooperate with endothelial cells to
form a vascular network, supporting the concept that
pericytes are members of the adult multipotent MSCs
family [11-15]. Because of these similarities and to over-
come the difficulties to isolate primary pericytes, as re-
ported by several authors [16,17], in our work we used
MSCs as pericytes. Furthermore, we already reported
that SSc-MSCs have been shown to be an alternative
system for studying the contribution of pericytes in the
pathogenesis of SSc [18].
Vascular endothelial growth factor A (VEGF) is a key
growth factor, involved in the reparative angiogenesis,
after injuries [19,20]. In addition to this well known ef-
fect, this molecule may induce perivascular cells to pro-
duce connective tissue growth factor (CTGF), which
stimulates extracellular matrix production and fibrosis
[21]. In fact, in presence of CTGF, pericytes differentiate
toward a migratory and myofibroblast phenotype [22].
VEGF has been suggested to be involved in the patho-
genesis of SSc and its expression is markedly increased
in different cell types, both in the epidermis and dermis
of patients with SSc and in the bloodstream, correlating
with organ manifestations [23,24]. At present, many
different isoforms of VEGF family are known, such as
VEGF121, VEGF189, and VEGF165, and recently, a new
VEGF165 isoform (VEGF165b), generated through alter-
native splicing, with a possible antiangiogenic effect, has
been described [25]. Although a switch from proangio-
genic to antiangiogenic isoforms has been recently de-
scribed in SSc patients [26], available literature showed
conflicting results about the potential inhibitory role of
this isoform [25,27]. VEGF exerts its functions by bind-
ing to the tyrosine kinase receptors VEGF receptor 1
(VEGFR1) and VEGF receptor 2 (VEGFR2). The tridi-
mensional VEGFR organization, on cell surface, modu-
lates the transmission of its specific signal. It is well
known that the cell surface proteins trafficking is regu-
lated by the lipid rafts microdomains which are present
in the plasma membranes. Caveolae are special structures
of lipid raft, which may be detected by electron microscopy
as flask shaped invaginations in the cell surface membrane
[28,29]. These structures are enriched in cholesterol and
may be distinguished from other structures of the lipid raftby the presence of a specific molecular family: the caveolin
scaffolding proteins, which are essential for caveolae forma-
tion and cholesterol binding [30-32]. Caveolin-1 (Cav-1) is
a member of this family and it is involved in the regulation
of signaling activity, via a direct interaction of its scaffolding
domain with a consensus sequence present in several
signaling proteins, including VEGFR2 [33]. Of note, the
interaction of Cav-1 with the signal transducing proteins,
has been shown to inhibit the activity of the latters. On
these bases, Cav-1 may play an important role in VEGF-
induced signaling, promoting VEGFR2 degradation by
caveolin-mediated transport to proteasome, under specific
conditions.
Conflicting results have been published on available
literature concerning Cav-1 in SSc. Lower levels of
Cav-1 were found in SSc lung fibroblasts and linked to
constitutive activation of JNK, ERK, and Akt signaling,
leading to overexpression of profibrotic markers such as
collagen and alpha smooth muscle actin [34]. Del Galdo
et al. [35] showed, in dermal fibroblasts, a downregula-
tion of Cav-1 in SSc skin and suggested that this finding
may contribute to the increased collagen deposition via
the activation of canonical transforming growth factor
(TGF-b) pathway. Haines et al. [36] showed that Cav-1
is a positive regulator of both TGF-b and CTGF genes
expression and signaling in human dermal fibroblasts
and they found increased levels of Cav-1 in SSc
fibroblasts.
The goal of this work was to evaluate whether an
alterations in Cav-1 expression, affecting perivascular
cells, may contribute to the pathogenic events leading to
fibrosis during SSc, via the persistence of the VEGF
signaling in the these cells. In this work, we provide evi-
dence that a downregulation of Cav-1 in MSCs, isolated
from SSc patients, strongly supports the pro-fibrotic
effect of VEGF165, whose role in SSc has been largely
explored [23-26]. In fact, an impairment of Cav-1 medi-
ated internalization and degradation of VEGFR2 leads to
a vicious loop, with redundant effects of VEGF signaling
and consequent increased CTGF production. Furthermore,
to better clarify the mechanisms linking the loss of Cav-1 to
the abnormal persistent VEGF signaling in SSc, we silenced
Cav-1 expression in HC-MSCs by specific siRNA, and ob-
served that the decreased Cav-1 expression in HC-MSC is
associated to a persisting VEGF signaling and CTGF pro-
duction, mirroring the results observed in SSc-MSCs.
These data confirm the lack of Cav-1 in perivascular cells
may lead to an aberrant production of CTGF, which may
contribute to the progression of fibrosis in SSc patients.
Results
Cav-1 levels are decreased in SSc-MSCs
The immunofluorescence staining showed that in the
unstimulated HC-MSCs, Cav-1 was primarily expressed
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15 min, Cav-1 was internalized to the cytoplasm as
shown by intracellular and perinuclear staining. On the
contrary, an impairment of the Cav-1 trafficking was ob-
served in the SSc cells, associated to a decreased surface
expression of Cav-1, in both limited SSc (lSSc) and dif-
fused (dSSc)-MSCs (Figure 1A).
Before VEGF treatment, in both lSSc- and dSSc-MSCs,
independent from the duration of the disease, mRNA
levels of Cav-1 were significantly lower when compared
with basal HC-MSCs expression (Cav-1 mRNA levels:
0.45 (range, 0.34 to 0.58) in lSSc-MSCs and 0.49 (range,
0.34 to 0.60) in dSSc-MSCs, both vs. 1.21 (range, 0.89-
1.43) in HC-MSCs, P <0.0001 and P = 0.0008, respect-
ively). After 15 min of VEGF administration, the mRNA
Cav-1 levels markedly increased in both SSc- and HC-
MSCs (Cav-1 mRNA levels: 1.34 (range, 1.02 to 1.56) in
lSSc-MSCs and 1.46 (range, 1.23 to 1.56) in dSSc-MSC,
both vs. 2.04 (range, 1.70 to 2.13) in HC-MSCs,
P <0.0001 and P = 0.0007, respectively) (Figure 1B).
Western blot analyses of the proteins obtained with dif-
ferent buffers, confirmed that decreased production of
Cav-1, in lSSc- as well as in dSSc-MSCs, confirming
that, the treatment with VEGF induces, on one hand, a
significant upregulation of Cav-1 and, on the other hand,
its phosphorylation at Y14. Both the Cav-1 protein levels
and its phosphorylation were significantly lower in SSc-
MSCs when compared to those observed in HC cells
(Figure 1C and 1D).
The Cav-1 downregulation is associated with an impaired
VEGFR2/Cav-1 co-localization in SSc-MSCs
By double staining immunofluorescence assay, after VEGF
treatment, a strong VEGFR2/Cav-1 co-localization was
observed in HC-MSCs. On the contrary, in the SSc-
MSCs, a lack of VEGFR2/Cav-1 co-localization was ob-
served (Figure 2A). To further explain these results an
immunoprecipitation assay was performed, and our re-
sults are showed in Figure 2B. After VEGF treatment,
VEGFR2 protein was detected in Cav-1 immunopre-
cipitates obtained from HC-MSCs protein extracts; on
the contrary, in SSc-MSCs the Cav-1/VEGFR2 co-
localization was absent.
Reduced ubiquitination of VEGFR2 involve an increase of
VEGF signaling in SSc-MSCs
Unstimulated and stimulated MSCs, from both SSc pa-
tients and HC, were lysed and VEGFR2 was successively
immunoprecipitated and analyzed by an anti-ubiquitin
antibody, because of VEGFR2 should undergo ubiquiti-
nation before degradation. Our experiments showed
that, in HC-MSCs, the VEGF receptor was ubiquitinated
after VEGF administration, thus confirming that physio-
logical degradation process started, after stimulation. Onthe contrary, in SSc-MSCs the levels of ubiquitin were
significantly lower (Figure 3A), suggesting an impaired
process of VEGFR2 degradation.
To confirm that, an impaired ubiquitination of
VEGFR2 in SSc-MSCs, might modulate an increasing
VEGF signaling, we investigated the PI3-kinase-Akt
pathway, which has been reported to play a central role
in VEGF activity [13]. We observed, by immunoblot ana-
lysis of VEGFR2 immunoprecipitates from HC-MSCs,
that VEGF stimulation promoted the tyrosine phosphor-
ylation of VEGFR2 and its interaction with PI3-kinase
p85 subunit (Figure 3B). On the contrary, in SSc-MSCs,
after VEGF treatment the tyrosine phosphorylation of
VEGFR2 was markedly increased when compared to
healthy cells. Furthermore, after VEGF treatment, we
observed, by western blot, that the levels of phosphory-
lated Akt were significantly higher in SSc-MSCs when
compared to HC-MSCs (Figure 3C).VEGF induces CTGF expression in SSc-MSCs
The CTGF gene expression was assessed by qRT-PCR.
Before VEGF treatment, CTGF mRNA levels in both
forms of SSc, independent of the disease duration, were
higher than those observed in HC-MSCs (CTGF mRNA
levels: 4.12 (range, 3.24 to 4.87) in SSc-MSCs vs. 1.16
(range, 0.88 to 1.78) in HC-MSCs, P <0.0001). The
VEGF stimulation significantly increased the CTGF gene
expression, both in HC- and SSc-MSCs, and of note, the
CTGF mRNA levels of SSc-MSCs were again signifi-
cantly higher than those observed in HC-MSCs (CTGF
mRNA levels: 10.17 (range, 8.46 to 11.87) in SSc-MSCs
vs. 6.32 (range, 5.35 to 7.19) levels in HC-MSCs, P <0.0001)
(Figure 4A). The western blot analysis confirmed the
mRNA results (Figure 4B).Increased VEGF signaling and CTGF production in HC-
MSCs treated with Cav-1-siRNA
To investigate the functional role of Cav-1 loss in HC-
MSCs, we employed RNA interference. In Figure 5A, we
showed that in Cav-1-siRNA treated HC-MSCs, a transi-
ent silencing of Cav-1 was observed, when compared to
cells treated by negative non-targeting siRNA (NT). In
Cav-1-siRNA treated HC-MSCs, the immunoblot ana-
lysis of VEGFR2 immunoprecipitates showed that VEGF
stimulation promoted an increased tyrosine phosphoryl-
ation of the receptor and its interaction with PI3-kinase
p85 subunit, whose levels were significantly increased
when compared to NT HC-MSCs (Figure 5B). Further-
more, VEGF stimulation increased the CTGF gene expres-
sion, both in Cav-1-siRNA and NT treated HC-MSCs,
although the CTGF protein expression of Cav-1-siRNA
HC-MSCs was significantly higher than those observed in
NT HC-MSCs (Figure 5C).
Figure 1 Cav-1 modulation in SSc-MSCs. (A) Immunofluorescence staining of Cav-1 in limited and diffused SSc-MSCs and HC-MSCs. The
pictures showed an impairment of the Cav-1 trafficking in SSc cells. Pictures are representative of all experiments. Original magnification 20X. (B)
Cav-1 mRNA levels of expression. After 15 min of VEGF treatment, the mRNA Cav-1 levels were markedly increased, in both HC- and SSc-MSCs,
and the values were significantly higher in HC-MSCs vs. SSc-MSCs. Each experimental condition was performed in triplicate. All the results are
expressed as Median (range) ***P <0.0001. (C) Western blot analysis of Cav-1 and Cav-1-phosphorilation (p-Cav-1) in HC- and SSc-MSCs, using
neutral detergent. The western blot analysis confirmed the decrease of Cav-1 expression in SSc-MSCs and showed that VEGF induced a significant
upregulation and a tyrosine phosphorylation of Cav-1, although the levels were significantly lower in SSc-MSCs when compared with HC cells.
Each experimental condition was performed in triplicate. Blot was representative of all the experiments. The values were expressed as arbitrary unit of
optical density (OD) (**P <0.001; ***P <0.0001). (D) Western blot analysis of Cav-1 and Cav-1-phosphorilation (p-Cav-1) in HC- and SSc-MSCs, using SDS.
The results obtained by using a different buffer mirror those obtained by neutral detergent. The values were expressed as arbitrary unit of
OD (**P <0.001; ***P <0.0001).
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Fibrosis, characterized by excessive extracellular matrix
accumulation, is the hallmark of SSc. Experimental stud-
ies suggest that a complex network including endothelial
cells, pericytes, fibroblasts, and immune cells may lead
to the pathogenic events of the disease. Many cytokines
such as TGF-b, VEGF, CTGF, and endothelin-1 are con-
sidered as key mediators in this process, because of their
skill to induce the differentiation of fibroblasts toward a
myofibroblastoid phenotype [21,37].
A better understanding of the mechanisms that form
an initial vascular alteration leading to a fibrotic re-
sponse might suggest new potential targets for anti-
fibrotic therapies of SSc. In this light, recent studies
focused on the differentiantive ability of perivascular
cells toward myofibroblast in fibrotic disorders. Dulauroy
et al. [38], showed that the perivascular cells derivedFigure 2 Impaired Cav-1/VEGFR2 co-localization in SSc-MSCs. (A) Imm
from HC and SSc. In unstimulated HC-MSCs, Cav-1 (2) is aggregated in som
diffuse. After treatment with VEGF both VEGFR2 and Cav-1 (4-6) were co-lo
co-localization (7-12), after VEGF treatment. Pictures are representative of all exp
and its association with VEGFR2 was assessed by western blot (WB). The immun
SSc-MSCs. Each experimental condition was performed in triplicate. Blot was rep
were quantified by densitometry and the values were expressed as arbitrary unfrom mesenchymal lineage differentiated toward myo-
fibroblast in an experimental model of kidney fibrosis.
Furthermore, pericytes were shown to be the major
source of myofibroblasts, thus opening new perspec-
tive about the role of perivascular cells in fibrosis.
In this work, using MSCs isolated from bone marrow
of SSc patients, which are largely accepted as an alter-
native source of functional pericytes [11-15,18], we
provide evidence that these cells display a failure in
Cav-1 trafficking inside the cell, which lead to a signifi-
cant decrease of VEGFR2 proteosomal degradation,
upregulation of the VEGF downstream pathways,
and finally, a consequent increased expression of
CTGF. This abnormal persistent VEGF signaling in
SSc perivascular mesenchymal cells, associated with an
increased expression of CTGF, which is a pivotal cyto-
kine involved in the development of tissue fibrosis,unofluorescence staining of Cav-1 (green) and VEGFR2 (red) in MSCs
e areas of the cell surface while the VEGFR2 (1) is ubiquitously
calized. In the SSc-MSCs, we observed an impaired VEGFR2/Cav-1
eriments. Original magnification 20X. (B) Cav-1 was immunoprecipitated (IP)
oprecipitation assay showed a lack of that Cav-1/VEGFR2 co-localization in
resentative of all the experiments. Co-immunoprecipitated protein bands
it of optical density (OD) (**P <0.001).
Figure 3 Impaired ubiquitination of VEGFR2 and increased VEGF signaling in SSc-MSCs. (A) VEGFR2 was immunoprecipitated (IP) and its
association with ubiquitin was assessed by western blot (WB). The immunoprecipitation assay showed that in HC-MSCs, after VEGF treatment, the
VEGFR2 immunoprecipitated complexes contained ubiquitin. In SSc-MSCs a decreased level of Ubiquitin associated to the VEGFR2 was observed.
(B) Proteins immunoprecipitated (IP) with VEGFR2 antibodies were fractionated by SDS-polyacrylamide gel electrophoresis. Immunoblots were
probed with an antibody to phosphotyrosine (pY) and p85. After VEGF treatment, the tyrosine phosphorylation of VEGFR2 in SSc-MSCs was
markedly increased when compared to HC-MSC. (C) Western blot of phosphorylated Akt and total Akt. In SSc-MSCs, after VEGF treatment, the
levels of p-Akt were higher when compared to HC. Each experimental condition was performed in triplicate. The blots in A-B-C were representative of all
the experiments. Protein bands were quantified by densitometry and the values were expressed as arbitrary unit of optical density (OD) (***P <0.0001).
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Figure 4 CTGF expression in SSc-MSCs. (A) qRT-PCR analysis of mRNA expression of CTGF, before and after VEGF treatment. Each experimental
condition was performed in triplicate. All the results are expressed as Median (range) (***P <0.0001). (B) Western blot of CTGF expression. VEGF
stimulation increased CTGF proteins levels in both SSc-ubiquitously and HC-MSCs, with a significantly higher expression in SSc-MSCs. Each experimental
condition was performed in triplicate. Blot was representative of all the experiments. The values were expressed as arbitrary unit of optical
density (OD) (**P <0.001; ***P <0.0001).
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tential therapeutic target in SSc.
The VEGF signaling activation involves its binding to
VEGFR2 and consequent internalization into the cyto-
plasm. The endocytosis of the receptor tyrosine kinases
(RTKs) family may be divided into two different steps:
the first step is internalization by translocation from the
cell surface into intracellular vesicles. Internalization
mainly controls the number of cell surface receptors and
the sensitivity of the cell to incoming signal. In the sec-
ond step, internalized receptors are sorted through a
complex system of intracellular vesicle compartments,
known as endosomes [39-41]. From early endosomes,
which are characterized morphologically by small size and
proximity to the plasma membrane [42], incoming ligand-
receptor complexes are sorted into two different fates: re-
cycling or degradation compartments. At present, it is wellknown that a dysfunctional regulation of RTKs endocytosis
may promote uncontrolled activation of signaling [43].
Two different internalization pathways have been pos-
tulated for VEGFR2: the Caveolae-mediated endocytosis
and the Clathrin-mediated internalization. The central
question of whether or not VEGFR2 uses caveolar route
for internalization cannot be unambiguously answered
based on available data [44].
Caveolae are plasmalemmal caveolin-coated invagi-
nations with trafficking functions, whose activity de-
pends by the main protein Cav-1. Cav-1 oligomers
constitute the filaments covering the cytosolic surface
of caveolae [45]. These oligomers form a scaffold for
the assembly of many signaling molecules, including
receptors, their ligands, and signal transducers, thus
regulating the activation and degradation state of these
complexes [46].
Figure 5 Downregulation of Cav-1 in HC-MSCs by Cav-1-siRNA impaired VEGF signaling. (A) HC-MSC was transfected with specific Cav-1-siRNA
(siRNA) or non-targeting siRNA (NT), and Cav-1 protein expression was evaluated by western blot. The cells transfected with Cav-1-siRNA showed a decreased
protein expression of Cav-1 when compared with cells transfected with NT siRNA. (B) Proteins immunoprecipitated (IP) by VEGFR2 antibodies were fractionated by
SDS-polyacrylamide gel electrophoresis. The immunoblots were probed, by using specific antibodies against phosphotyrosine (pY) and p85. In siRNA HC-MSCs,
after VEGF treatment, the tyrosine phosphorylation of VEGFR2 was significantly increased when compared to NT MSCs. (C)Western blot of CTGF expression.
VEGF stimulation significantly increased CTGF proteins levels in siRNA HC-MSCs, when compared to NT HC-MSCs. Each experimental condition was performed
in triplicate. Blot was representative of all the experiments. The values were expressed as arbitrary unit of optical density (OD) (*P <0.01; **P <0.001; ***P <0.0001).
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erature, concerning the possibility that VEGF may
modulate the Cav-1 expression, probably due to the dif-
ferent cell types (endothelial, mesangial, fetoplacental ar-
tery endothelial cells) used in the experiments [47-49].
Furthermore, no data are available about the VEGFR2/
Cav-1 interaction and its functions in MSCs. Normally,
in the unstimulated state, caveolae are static structures,
but after surface receptor stimulation, caveolae form ac-
tive intracellular vesicles. Phosphorylation of Cav-1
(Y14) by Src kinase are required for caveolar fission [44].
The localization of both receptors and signaling partners
to caveolae, has been considered a pivotal mechanism to
control the levels of both receptors and signaling pro-
teins, their availability, and activation.
In our work, we showed that in MSCs VEGF upregu-
lates the levels of Cav-1 and its phosphorylation, sug-
gesting that this mechanism may be involved in the
following VEGFR2 activation. Conflicting results have
been recently published concerning the optimal
methods to evaluate the caveolae-associated Cav-1
[47,49,50]. Thus, in this paper, we lysed the cells by
using neutral detergent, which completely dissolved
the Cav-1 associated lipid micro-domains, or alterna-
tively SDS, which did not detach the Cav-1 molecule
from the caveolae. Independently of the constituents of
buffer in SSc-MSCs stimulated and unstimulated by
VEGF, the Cav-1 levels and its phosphorylation were
always significantly lower when compared to HC-
MSCs. Moreover, in untreated HC-MSCs, Cav-1 was
primarily localized at the plasma membrane, and, after
VEGF treatment, Cav-1 was internalized into the cyto-
plasm around the perinuclear area. On the contrary,
this vesicular trafficking was significantly impaired in
SSc-MSCs.
To assess the pathogenetic implication of the re-
duced Cav-1 expression in the specific trafficking and
signaling of VEGFR2 during SSc, we evaluated the
Cav-1/VEGFR2 co-localization, after VEGF stimulus.
Our data showed that in SSc-MSCs this molecular co-
localization was significantly impaired, when compared
to HC-MSC and these data were confirmed by IF and
immunoprecipitation.
The signaling of VEGF starts after VEGFR2 internal-
ization and the fate of activated receptors depends on its
transport to late endosome for degradation, or alterna-
tively for recycling. Several studies, carried out on differ-
ent RTKs suggest that the transport to late endosome
should be mediated by Cav-1 [51,52] and a decrease of
Cav1 may result in enhanced growth factor signaling
[51]. The receptor degradation occurs in the prote-
asome. It recognizes and rapidly degrades ubiquitinated
proteins involved in the regulation of transcription,
cell cycle progression, apoptosis, signal transduction,and angiogenesis [53,54]. Ubiquitin is a conserved 76-
amino-acid polypeptide, activated by an ubiquitin-
activating enzyme (E1) in an ATP-dependent manner
and it is transferred to an ubiquitin-conjugating enzyme
(E2). Furthermore, an ubiquitin-protein ligase (E3) spe-
cifically attaches ubiquitin to a target protein by an
amino group of a lysine residue. E3 ubiquitin ligases are
a large family of proteins that are known to be involved
in the regulation of turnover and activity of many target
proteins. Although it has been established that VEGFR2
is ubiquitinated in a ligand-dependent manner in re-
sponse to VEGF [53], the role of ubiquitination in VEGF
signaling is still unclear. Several ubiquitin ligases are
known to be involved in VEGFR2 degradation and at-
tenuation of signaling [55]. Earlier studies established
that an E3 ubiquitin ligase, Nedd4, modulates the pro-
teasomal degradation of VEGFR2, and that this degrad-
ation might be inhibited by the sequestration of Nedd4
[54]. It may be considered that the amount of ubiqui-
nated VEGFR2, co-localizing with Cav-1 [33,55-57] may
be carried to degradation, following the same fate of
other RTKs [44]. We observed that the levels of ubiquiti-
nated VEGFR2, after VEGF treatment, were significantly
reduced in SSc-MSC and this decreased level of ubiquitina-
tion might contribute to upregulation of VEGF signaling. In
fact, different studies showed that ubiquitin-mediated pro-
teolysis plays an important role in the regulation of many
cellular processes, including receptors activity, by facilitat-
ing the timely destruction of key proteins [58-60]. It is well
known that VEGF may induce CTGF production [59], and
in this setting we observed that following the increased
VEGF signaling in SSc-MSCs, a consequent increased ex-
pression of CTGF may be shown. This molecule, also
known as CCN2, is a member of the CCN (CCN1-6) family
of matricellular proteins. Many studies focused on the role
of CTGF in increasing ECM production, during fibrosis
[61]. CTGF is generally overexpressed in all fibrotic
conditions, and induces collagen type I deposition [62]
and it has been suggested to play a crucial role in SSc
tissue fibrosis [61-64]. It has been shown to induce
fibroblast proliferation, cell adhesion, and stimulation
of extracellular matrix production [65]. it has been
reported that VEGF is able to modulate CTGF produc-
tion [21], in fact, VEGF may affect both the prolifera-
tion of fibrocellular components and the wound
healing process, via CTGF induction [19,20]. Interest-
ingly, the SSc-MSCs production of CTGF was signifi-
cantly higher when compared with healthy cells and
the increased levels of VEGF observed in SSc patients
[23] may contribute to the over expression of CTGF,
which plays different physiological roles, not only in fi-
brotic process but also in angiogenesis, such as the
maintenance of capillary strength via the extracellular
matrix production [66,67].
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VEGF signaling and CTGF modulation, we silenced the
Cav-1 expression in HC-MSCs. We showed that the
downregulation of Cav-1 induced a significant increase
in VEGFR2 phosphorylation and its interaction with
PI3-kinase p85 subunit, which is associated to an in-
crease of VEGF signaling, in knockdown cells, when
compared to NT HC-MSCs, thus mirroring the same re-
sults observed in SSc-MSCs.
This Cav-1 downregulation further strengthens our
data in SSc patients, and supports the hypothesis that
the loss of Cav-1 in SSc-MSCs may be involved in the
molecular pathogenetic steps of the disease, and linking
the earlier vascular damages to the subsequent fibrosis.
Conclusion
This is the first paper, in our knowledge evaluating the
function of Cav-1 on the VEGF signaling in SSc, and
particularly on MSC/pericyte lineage [1], showing that
these pathways may strongly influence fibrotic process
during scleroderma. These data underline the potential
role of Cav-1 in fibrotic diseases and suggest this mol-
ecule as a possible therapeutic target in the disease. Fur-
thermore, the evidence of an impaired expression and
function of Cav-1 in perivascular SSc cells strongly con-
firms the potential role of the MSCs/pericytes in thisTable 1 Clinical and demographic features of the 20 SSc patie
Sex/Age (years) Year of SSc onset MRSS Autoantibodies Lung in
F/22 2009 14 ANA/ACA Normal/
F/45 1998 13 ANA/ACA Normal/
M/43 1985 18 ANA/ACA Normal/
F/26 2003 8 ANA/ACA Normal/
F/39 1980 15 ANA/ACA Normal/
F/40 2002 8 ANA/ACA Fibrosis/
M/45 2000 10 ANA/ACA Normal/
F/21 2010 13 ANA/ACA Normal/
F/30 2000 9 ANA/ACA Fibrosis/
F/22 2008 11 ANA/ACA Normal/
F/40 1978 12 ANA/Scl-70 Normal/
F/41 2001 10 ANA/Scl-70 Fibrosis/
F/23 2007 13 ANA/Scl-70 Normal/
F/46 2007 12 ANA/Scl-70 Normal/
F/21 2007 13 ANA/Scl-70 Normal/
F/31 2000 15 ANA/Scl-70 Normal/
F/36 1999 20 ANA/Scl-70 Normal/
F/20 2008 11 ANA/Scl-70 Normal/
F/41 2004 20 ANA/Scl-70 Normal/
F/30 2007 10 ANA/Scl-70 Normal/
ACA = anti-centromere antibodies ANA = antinuclear antibodies; HRCT = high resolu
(maximum possible score 51); PFT = pulmonary function test.pathologic process probably in the earlier phases of the
disease following the initial endothelial injury. Taken to-
gether our data suggest that MSCs/pericytes lineage, lo-
calized in the perivascular niches, may be a potential
cellular target in SSc and open new perspectives in the
field of MSC transplantation and regenerative medicine
in scleroderma.
Methods
Isolation, culture, immunophenotyping, and
differentiation of MSCs
After approval of San Salvatore University Hospital eth-
ics committee and written informed consent from pa-
tients, primary MSCs were obtained from 20 SSc
patients, 10 lSSc, and 10 dSSc by aspiration from the
posterior superior iliac crest. Demographic and clinical
characteristics of the patients are showed in Table 1.
Patients discontinued corticosteroids, oral vasodilators,
intravenous prostanoids, or other potentially disease-
modifying drugs, at least 1 month before biopsies. None
assumed immunosuppressants. Ten frozen BM-MSCs
samples obtained from age-matched healthy women
bone marrow donors were used as control. Both SSc-
and HC-MSCs were cultured and characterized as previ-
ously described [33]: plated at concentration of 2 × 105
cells/cm2 in Dulbecco’s Mod Eagle Medium (D-MEM,nts
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fetal bovine serum (Standard South America origin,
Lonza, Walkersville, MD, USA), 2 mmol/L L-glutamine
(EuroClone, Milan, Italy), and 100 U Penicillin, 1,000 U
Streptomycin (Biochrom AG, Miramar, FL, USA). At
80% confluence the MSCs were split and subcultured.
Third-passage (P3) MSCs were analyzed for the sur-
face expression of mesenchymal antigens (CD45, CD73,
CD90, CD34, CD79a, PDGFRβ) and pericyte markers
(α-SMA, SM22α, NG2, desmin, RGS5) as previously de-
scribed [33].MSCs treatment with VEGF
To establish the optimal concentration of VEGF165 (R &
D, USA), in our system, a dose/response curve was per-
formed, using P3 MSCs obtained from both one control
and one patient.
Each experiment was performed in triplicate and the
optimal stimulation dose for VEGF was always assessed
to be 50 ng/mL.Immunofluorescence
Cells were placed in eight wells culture slides (BD, USA)
and treated with VEGF 50 ng/mL for 15 min. Control
cells were cultured in basal medium. For the staying, the
cells were incubated with Cav-1 and VEGFR2 antibodies
(Santa Cruz Biotechnology, CA, USA). After, the cells
were incubated with secondary antibodies (Alexa Fluor
488-conjugated and Alexa Fluor 555-conjugated, Invitro-
gen, USA) and counterstained using 4′, 6-diamidino-2-
phenylindole (DAPI). Images were acquired using an
Olympus BX53 fluorescence microscope.qRT-PCR analysis
Total RNA was extracted from VEGF treated and un-
treated MSCs using TRIZOL (SIGMA, USA) and reverse
transcribed into complementary DNA (cDNA) with the
ThermoScript reverse transcription-PCR system (Invitro-
gen, CA, USA). The qRT-PCR was performed by using
SYBR green kits (Applied Biosystems, The Netherlands).
Results were analyzed after 45 cycles of amplification using
the ABI 7500 Fast Real Time PCR System. Primers were
designed on the basis of the reported sequences (Primer
bank NCBI; CTGF: 5′-CAGCATGGACGTTCGTCTG-3′
(forward) and 5′-AACCACGGTTTGGTCCTTGG-3′
(reverse); Cav-1: 5′-AATACTGGTTTTACCGCTTG
CT-3′ (forward) and 5′-CATGGTACAACTGCCCA
GATG-3′ (reverse); β-actin: 5′-CCTGGCACCCAG
CACAAT-3′ (forward) and 5′-AGTACTCCGTGTG
GATCGGC-3′ (reverse)). The qRT-PCR was run in
triplicate.RNA interference
For silencing of Cav-1 expression, HC-MSCs were trans-
fected with Silencer Select Cav-1-siRNA (Life Technolo-
gies, USA) or with Silencer Select Negative Control
non-targeting siRNA (NT) (Life Technologies, USA)
using Lipofectamine™ 3000 (Life Technologies, USA).
Transfection was performed according to the manufac-
turer’s instructions. Briefly, HC-MSCs were plated at 1 ×
104 cells per cm2, 24 h prior to transfection. Cultures
were incubated for 24 h with 25 pmol of siRNA in 2 mL
of OptiMem. After incubation, plates were washed and
cells were allowed to recover in normal growth condi-
tions (10% DMEM) for 24 h post-transfection.
Western blot
In order to perform western blot assays, HC- and SSc-
MSCs, before and after treatment, were pelleted, washed
twice with PBS, lysed on ice in lysis buffer (1% Triton X-
100, 0.5% NP-40, 50 mM Tris-Cl, pH 7.5, 150 mM NaCl,
1 mM EDTA, supplemented with 1 mM phenylmethyl-
sulfonyl fluoride, 1 mM NaF, 1 mM Na3VO4, 5 μg/mL
aprotinin, 5 μg/mL leupeptin) for 30 min, and cleared by
centrifugation [49]. Due to the reported data that neutral
detergent, such as Triton X-100, does not identify the
amount of caveolae-associated Cav-1 [50], six SSc-MSCs
(3 lSSc and 3 dSSc) and three HC-MSCs, before and
after treatment, were pelleted, washed twice with PBS,
solubilized with a different sample buffer, containing
0.125 M Tris-HCl (pH 6.8), 5% (w/v) SDS, 2.5% (v/v)
b-mercaptoethanol, 5% glycerol in double distilled
water [47].
The protein concentration was calculated by Bradford
protein assay reagent (Bio-Rad). A total of 50 μg of pro-
teins were separated by SDS-PAGE and transferred to
nitrocellulose membranes. After 1 h blocking at room
temperature in blocking buffer (5% not fat milk in Tris-
buffered saline/1% tween 20 (TBS/T)) and after washing
three times for 5 min each in TBS/T, the membranes
were incubated overnight at 4°C with the primary anti-
bodies: Cav-1 and phospho-Cav-1 (Y14) (Santa Cruz
Biotechnology, CA, USA), phospho-Akt and Akt (New
England Biolabs, MA, USA) and CTGF (R & D Systems,
MN, USA), diluted in 5% bovine serum albumin in TBS/
T. Following three washes with TBS/T, horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz,
Biotechnology, CA, USA) diluted in blocking buffer was
added for 30 min at room temperature and washed three
times with TBS/T. The detection was performed by
enhanced chemiluminescence detection ECL reaction
(Amersham Pharmacia Biotechnology). Tubulin signal
(CP06 Anti-α-Tubulin Mouse mAb-DM1A) was used as
loading control. Immunoreactive bands were quantified
with densitometry using ImageJ software (NIH, Bethesda,
MD, USA).
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Cells were washed three times with cold phosphate-
buffered saline and solubilized in 200 μL of lysis buffer
(TrisHCl 10 mM, ph 7,4, NaCl 100 mM, EDTA 1 mM,
EGTA 1 mM, Triton 1%, NP-40 0,5%, NaF 50 mM,
Na3VO4, PMSF 1 mM, Leupeptin 10 μg/mL, Aprotinin
10 μg/mL).
After centrifugation at 12,000 rpm for 10 min, 0.5 mg of
protein was subjected to immunoprecipitation. Specific
rabbit anti-Cav-1 and anti-VEGFR2 antibodies (Santa Cruz
Biotechnology, CA, USA) was added and rocked at 4°C for
1 h; 30 μL protein A/G beads (Santa Cruz) was added and
the sample was rocked over night at 4°C.
For western blotting, anti-VEGFR2 (Santa Cruz
Biotechnology, CA, USA), anti-Cav-1 (Santa Cruz
Biotechnology, CA, USA), anti-ubiquitin, anti-p85, and
anti-phosphotyrosine (Abcam, MA, USA) were used.
Statistical analysis
GraphPad Prism 5.0 software were used for statistical
analyses. Where not differently specified, our results are
expressed as Median (range), within a confidence inter-
val of 95%. Due to the non-parametric distribution of
our data the Mann-Whitney U test was used as appro-
priate for analyses. Statistical significance was expressed
by a P value <0.05.
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